ViGenCell Past Earnings Performance
Past criteria checks 0/6
ViGenCell's earnings have been declining at an average annual rate of -5.7%, while the Biotechs industry saw earnings growing at 3.8% annually. Revenues have been growing at an average rate of 161.6% per year.
Key information
-5.7%
Earnings growth rate
-3.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 161.6% |
| Return on equity | -25.0% |
| Net Margin | -27,672.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How ViGenCell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 56 | -15,358 | 3,231 | 12,830 |
| 30 Jun 24 | 55 | -15,314 | 3,182 | 13,630 |
| 31 Mar 24 | 0 | -17,269 | 3,194 | 15,168 |
| 31 Dec 23 | 0 | -17,875 | 3,449 | 15,452 |
| 30 Sep 23 | 0 | -17,411 | 3,543 | 14,836 |
| 30 Jun 23 | 0 | -18,740 | 3,942 | 14,855 |
| 31 Mar 23 | 0 | -17,871 | 4,410 | 13,352 |
| 31 Dec 22 | 0 | -17,393 | 4,774 | 12,285 |
| 30 Sep 22 | 0 | -16,595 | 5,004 | 10,910 |
Quality Earnings: A308080 is currently unprofitable.
Growing Profit Margin: A308080 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A308080's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare A308080's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A308080 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.8%).
Return on Equity
High ROE: A308080 has a negative Return on Equity (-25.03%), as it is currently unprofitable.